<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
450 Fifth Street, N.W.
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: April 28, 1995
Atrix Laboratories, Inc.
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-18231 84-1043826
- ------------------- ------------------- ----------------
(State of (Commission (IRS Employer
incorporation) File Number) Identification No.)
2579 Midpoint Drive, Fort Collins, Colorado 80525
----------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (970)482-5868
Not Applicable
--------------
(Former Name or Former Address, if Change Since Last Report)
<PAGE> 2
Item 5. Other Events.
See the Press Releases attached hereto as Exhibit 20.1 and Exhibit 20.2.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
20.1. Press Release dated April 28, 1995 regarding the
signing of a License Agreement with Paravax, Inc.
20.2. Press Release dated May 2, 1995 regarding the
signing of a License Agreement with Gensia, Inc.
<PAGE> 3
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ATRIX LABORATORIES, INC.
Date: May 10, 1995 By: /s/ Kimberly A. Marks
---------------------------------------
Kimberly A. Marks, Corporate Controller
<PAGE> 4
EXHIBIT INDEX
<TABLE>
<CAPTION>
EXHIBIT NO. EXHIBIT DESCRIPTION PAGE
- ----------- -------------------- ----
<S> <C> <C>
20.1. Press Release dated April 28, 1995 regarding the
signing of a License Agreement with Paravax, Inc.
20.2. Press Release dated May 2, 1995 regarding the
signing of a License Agreement with Gensia, Inc.
</TABLE>
<PAGE> 1
Exhibit 20.1.
FOR IMMEDIATE RELEASE: CONTACT: John E. Urheim
April 28, 1995 Vice Chairman & CEO
Atrix Laboratories, Inc.
(970)482-5868
OR: Melissa Wilmoth
Cameron Associates, Inc.
(212)644-9560
ATRIX SIGNS LICENSE AGREEMENT WITH PARAVAX TO DEVELOP
PERIODONTAL TREATMENT FOR COMPANION ANIMALS
FORT COLLINS, COLORADO, APRIL 28 -- Atrix Laboratories, Inc. (NASDAQ: ATRX),
and Paravax, Inc., Fort Collins, Colorado, today announced they have
consummated a worldwide license agreement to develop a product to treat
periodontal disease in companion animals.
Under the terms of the license, Atrix will develop a subgingival therapy for
periodontal disease in dogs and cats, comprised of the antibiotic doxycycline
and Atrix's unique ATRIGEL(TM) Drug Delivery System. The product is
administered into infected periodontal pockets as a liquid, which forms a solid
implant designed to release doxycycline for a period of several days as it
biodegrades, killing the bacteria associated with periodontal disease.
Atrix will be responsible for conducting laboratory studies and preparing
materials for clinical testing in dogs and cats, which will be conducted by
Paravax. Atrix will also be responsible for scale-up and manufacturing of
commercial quantities, which Paravax will market exclusively on a world-wide
basis. Paravax will fund elements of the development program, make certain
milestone payments, and purchase all of its required product from Atrix.
John Urheim, Atrix's Vice Chairman and Chief Executive Officer, stated "We
think that treatment of periodontal disease in animals is an excellent
application of our technology. As we begin development of products for animal
healthcare, we are pleased to be collaborating with Paravax, a local company
with a strong research and development focus in the veterinary field."
Fred M. Schwarzer, President of Paravax, said "Periodontal disease is a serious
and wide-spread health concern for companion animals: it is estimated that by
the age of three, a significant percentage of dogs and cats have some degree of
periodontal disease. The prevalence in dogs becomes almost universal as they
reach their later years. There are presently more than 50 million dogs and 60
million cats in the United States alone, which makes this a significant
marketing opportunity."
<PAGE> 2
Exhibit 20.1 continued:
Atrix Laboratories, Inc. is a drug delivery and medical device company whose
platform technology is comprised of the ATRIGEL(TM) biodegradable polymeric
system, which can be used for a broad range of applications including drug
delivery, medical devices, and the treatment of periodontal disease.
Paravax is a Fort Collins based, high technology companion animal health
company, formed to discover, develop and market novel pharmaceutical products
for the treatment, prevention and diagnosis of diseases of dogs, cats and
horses.
# # #
<PAGE> 1
Exhibit 20.2.
FOR IMMEDIATE RELEASE: CONTACT: JOHN E. URHEIM
MAY 2, 1995 VICE CHAIRMAN & CEO
ATRIX LABORATORIES, INC.
(970) 482-5868
OR: MARTHA L. HOUGH
GENSIA, INC.
(619) 546-8300
OR: MELISSA WILMOTH
CAMERON ASSOCIATES, INC.
(212) 644-9560
ATRIX SIGNS LICENSE AGREEMENT WITH GENSIA
TO DEVELOP CANCER TREATMENT
FORT COLLINS, CO, AND SAN DIEGO, CA, MAY 2 -- Atrix Laboratories, Inc. (NASDAQ:
ATRX), and Gensia, Inc. (NASDAQ: GNSA), today announced they have signed a
worldwide license agreement to develop a product to be sold by Gensia
Laboratories, Ltd. for the treatment of solid tumor cancers using Atrix's
ATRIGEL(TM) Drug Delivery System. Under the terms of the license, Atrix will
immediately begin a feasibility study to characterize release rates of an
existing anti-cancer drug when incorporated into Atrix's unique ATRIGEL Drug
Delivery System.
On successful completion of the feasibility study, Atrix will proceed with
development of a dosage form or forms to be evaluated in human clinical trials.
Gensia will be responsible for conducting the clinical trials, scale-up,
manufacture, marketing and distribution of commercial quantities of the
product. Gensia will also be responsible for funding the development program
at Atrix, will make certain milestone payments and pay a royalty on future
sales of the product.
The ATRIGEL System is administered as a liquid containing a drug, which forms a
solid implant when it comes in contact with a moist environment. The solid
implant is designed to biodegrade over an extended period of time, releasing
drug into the patient's bloodstream. Rather than providing therapy by daily
injections, the ATRIGEL System allows a single injection to provide drug
treatment for weeks or even months.
<PAGE> 2
Exhibit 20.2 continued:
"We think that treatment of solid tumor cancers is an excellent application of
our technology," stated John Urheim, Atrix's Vice Chairman and Chief Executive
Officer. "We are pleased to collaborate with Gensia, a company with existing
parenteral manufacturing expertise and a growing presence in the cancer
treatment field."
David F. Hale, Chairman, President and Chief Executive Officer of Gensia, Inc.
said "Our Gensia Laboratories subsidiary is targeting the cancer therapy
market, which is in excess of $1.2 billion and growing at a rate of
approximately 15% per year, as a growth market for its business. If
successfully developed, we believe this ATRIGEL product will contribute
significantly to the future growth of our multisource oncolytic product line at
Gensia Laboratories."
Gensia Laboratories, Ltd., a wholly-owned subsidiary of Gensia, Inc., is
located in Irvine, California and develops, manufactures and markets
multisource injectable drug products for the acute care market.
Gensia, Inc. is a fully integrated, research-based company focused on the
discovery, development, manufacture and marketing of health care products for
the acute care market.
Atrix Laboratories, Inc. is a drug delivery and medical device company whose
platform technology is comprised of the ATRIGEL biodegradable polymeric system,
which can be used for a broad range of applications including drug delivery,
medical devices, and the treatment of periodontal disease.
###
